Last reviewed · How we verify

NCT05325086

Effect on Quality of Life of Adapted Information in Pulmonary Rehabilitation in Chronic Respiratory Disease Patients

Completed NA Last updated 27 July 2023
What this trial tests

NA trial testing Adapted information arm in Chronic Respiratory Disease in 136 participants. Completed in 25 July 2023.

Timeline
5 April 2022
Primary endpoint
25 July 2023
25 July 2023

Quick facts

Lead sponsorKorian
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment136
Start date5 April 2022
Primary completion25 July 2023
Estimated completion25 July 2023
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Korian

Who can join

Adults 18 to 80, any sex, with Chronic Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the clinical study is to study the effect of health-related quality of Life of information aimed at reducing the impact of a personality trait (openness to experiences) identified as a risk of non-response to pulmonary rehabilitation in patients with chronic respiratory diseases. This study will determine if a specific information focusing on characteristics of openness to experiences personality trait will lead to better benefits than a general information.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Respiratory Disease

Currently open trials in the same condition.

Other Korian trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05325086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing